These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 35758878)

  • 1. Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.
    Moodie Z; Dintwe O; Sawant S; Grove D; Huang Y; Janes H; Heptinstall J; Omar FL; Cohen K; De Rosa SC; Zhang L; Yates NL; Sarzotti-Kelsoe M; Seaton KE; Laher F; Bekker LG; Malahleha M; Innes C; Kassim S; Naicker N; Govender V; Sebe M; Singh N; Kotze P; Lazarus E; Nchabeleng M; Ward AM; Brumskine W; Dubula T; Randhawa AK; Grunenberg N; Hural J; Kee JJ; Benkeser D; Jin Y; Carpp LN; Allen M; D'Souza P; Tartaglia J; DiazGranados CA; Koutsoukos M; Gilbert PB; Kublin JG; Corey L; Andersen-Nissen E; Gray GE; Tomaras GD; McElrath MJ
    J Infect Dis; 2022 Aug; 226(2):246-257. PubMed ID: 35758878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
    Laher F; Moodie Z; Cohen KW; Grunenberg N; Bekker LG; Allen M; Frahm N; Yates NL; Morris L; Malahleha M; Mngadi K; Daniels B; Innes C; Saunders K; Grant S; Yu C; Gilbert PB; Phogat S; DiazGranados CA; Koutsoukos M; Van Der Meeren O; Bentley C; Mkhize NN; Pensiero MN; Mehra VL; Kublin JG; Corey L; Montefiori DC; Gray GE; McElrath MJ; Tomaras GD
    PLoS Med; 2020 Feb; 17(2):e1003038. PubMed ID: 32092060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
    Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
    PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.
    Gray GE; Huang Y; Grunenberg N; Laher F; Roux S; Andersen-Nissen E; De Rosa SC; Flach B; Randhawa AK; Jensen R; Swann EM; Bekker LG; Innes C; Lazarus E; Morris L; Mkhize NN; Ferrari G; Montefiori DC; Shen X; Sawant S; Yates N; Hural J; Isaacs A; Phogat S; DiazGranados CA; Lee C; Sinangil F; Michael NL; Robb ML; Kublin JG; Gilbert PB; McElrath MJ; Tomaras GD; Corey L
    Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.
    Zhao LP; Fiore-Gartland A; Carpp LN; Cohen KW; Rouphael N; Fleurs L; Dintwe O; Zhao M; Moodie Z; Fong Y; Garrett N; Huang Y; Innes C; Janes HE; Lazarus E; Michael NL; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; De Rosa SC; Corey L; Gray GE; Seaton KE; Yates NL; McElrath MJ; Frahm N; Tomaras GD; Gilbert PB
    PLoS One; 2020; 15(1):e0226803. PubMed ID: 31999736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.
    McGuire EP; Fong Y; Toote C; Cunningham CK; McFarland EJ; Borkowsky W; Barnett S; Itell HL; Kumar A; Gray G; McElrath MJ; Tomaras GD; Permar SR; Fouda GG
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29021402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
    Moodie Z; Andersen-Nissen E; Grunenberg N; Dintwe OB; Omar FL; Kee JJ; Bekker LG; Laher F; Naicker N; Jani I; Mgodi NM; Hunidzarira P; Sebe M; Miner MD; Polakowski L; Ramirez S; Nebergall M; Takuva S; Sikhosana L; Heptinstall J; Seaton KE; De Rosa S; Diazgranados CA; Koutsoukos M; Van Der Meeren O; Barnett SW; Kanesa-Thasan N; Kublin JG; Tomaras GD; McElrath MJ; Corey L; Mngadi K; Goepfert P;
    PLoS Med; 2024 Mar; 21(3):e1004360. PubMed ID: 38502656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses.
    Huang Y; Alam S; Andersen-Nissen E; Carpp LN; Dintwe OB; Flach BS; Grunenberg N; Laher F; De Rosa SC; Ferrari G; Innes C; Bekker LG; Kublin JG; McElrath MJ; Tomaras GD; Gray GE; Gilbert PB
    Viruses; 2024 Aug; 16(9):. PubMed ID: 39339842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune correlates analysis of the Imbokodo (HVTN 705/HPX2008) efficacy trial of a mosaic HIV-1 vaccine regimen evaluated in Southern African people assigned female sex at birth: a two-phase case-control study.
    Kenny A; van Duijn J; Dintwe O; Heptinstall J; Burnham R; Sawant S; Zhang L; Mielke D; Khuzwayo S; Omar FL; Stanfield-Oakley S; Keyes T; Dunn B; Goodman D; Fong Y; Benkeser D; Zou R; Hural J; Hyrien O; Juraska M; Luedtke A; van der Laan L; Giorgi EE; Magaret C; Carpp LN; Pattacini L; van de Kerkhof T; Korber B; Willems W; Fisher LH; Schuitemaker H; Swann E; Kublin JG; Pau MG; Buchbinder S; Tomaka F; Nijs S; Lavreys L; Gelderblom HC; Corey L; Mngadi K; Gray GE; Borducchi E; Hendriks J; Seaton KE; Zolla-Pazner S; Barouch DH; Ferrari G; De Rosa SC; McElrath MJ; Andersen-Nissen E; Stieh DJ; Tomaras GD; Gilbert PB;
    EBioMedicine; 2024 Oct; 108():105320. PubMed ID: 39236556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial.
    Pitisuttithum P; Nitayaphan S; Chariyalertsak S; Kaewkungwal J; Dawson P; Dhitavat J; Phonrat B; Akapirat S; Karasavvas N; Wieczorek L; Polonis V; Eller MA; Pegu P; Kim D; Schuetz A; Jongrakthaitae S; Zhou Y; Sinangil F; Phogat S; Diazgranados CA; Tartaglia J; Heger E; Smith K; Michael NL; Excler JL; Robb ML; Kim JH; O'Connell RJ; Vasan S;
    Lancet HIV; 2020 Apr; 7(4):e238-e248. PubMed ID: 32035516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.
    Fouda GG; Cunningham CK; McFarland EJ; Borkowsky W; Muresan P; Pollara J; Song LY; Liebl BE; Whitaker K; Shen X; Vandergrift NA; Overman RG; Yates NL; Moody MA; Fry C; Kim JH; Michael NL; Robb M; Pitisuttithum P; Kaewkungwal J; Nitayaphan S; Rerks-Ngarm S; Liao HX; Haynes BF; Montefiori DC; Ferrari G; Tomaras GD; Permar SR
    J Infect Dis; 2015 Feb; 211(4):508-17. PubMed ID: 25170104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.
    Fong Y; Shen X; Ashley VC; Deal A; Seaton KE; Yu C; Grant SP; Ferrari G; deCamp AC; Bailer RT; Koup RA; Montefiori D; Haynes BF; Sarzotti-Kelsoe M; Graham BS; Carpp LN; Hammer SM; Sobieszczyk M; Karuna S; Swann E; DeJesus E; Mulligan M; Frank I; Buchbinder S; Novak RM; McElrath MJ; Kalams S; Keefer M; Frahm NA; Janes HE; Gilbert PB; Tomaras GD
    J Infect Dis; 2018 Mar; 217(8):1280-1288. PubMed ID: 29325070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.
    Zolla-Pazner S; deCamp A; Gilbert PB; Williams C; Yates NL; Williams WT; Howington R; Fong Y; Morris DE; Soderberg KA; Irene C; Reichman C; Pinter A; Parks R; Pitisuttithum P; Kaewkungwal J; Rerks-Ngarm S; Nitayaphan S; Andrews C; O'Connell RJ; Yang ZY; Nabel GJ; Kim JH; Michael NL; Montefiori DC; Liao HX; Haynes BF; Tomaras GD
    PLoS One; 2014; 9(2):e87572. PubMed ID: 24504509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
    Rerks-Ngarm S; Pitisuttithum P; Excler JL; Nitayaphan S; Kaewkungwal J; Premsri N; Kunasol P; Karasavvas N; Schuetz A; Ngauy V; Sinangil F; Dawson P; deCamp AC; Phogat S; Garunathan S; Tartaglia J; DiazGranados C; Ratto-Kim S; Pegu P; Eller M; Karnasuta C; Montefiori DC; Sawant S; Vandergrift N; Wills S; Tomaras GD; Robb ML; Michael NL; Kim JH; Vasan S; O'Connell RJ;
    J Infect Dis; 2017 Apr; 215(8):1255-1263. PubMed ID: 28329190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations.
    Akapirat S; Karnasuta C; Vasan S; Rerks-Ngarm S; Pitisuttithum P; Madnote S; Savadsuk H; Rittiroongrad S; Puangkaew J; Phogat S; Tartaglia J; Sinangil F; de Souza MS; Excler JL; Kim JH; Robb ML; Michael NL; Ngauy V; O'Connell RJ; Karasavvas N;
    PLoS One; 2018; 13(4):e0196397. PubMed ID: 29702672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa.
    Hanass-Hancock J; Carpenter B; Reddy T; Nzuza A; Gaffoor Z; Goga A; Andrasik M
    Trials; 2021 Dec; 22(1):897. PubMed ID: 34895272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.
    Williams LD; Shen X; Sawant SS; Akapirat S; Dahora LC; Tay MZ; Stanfield-Oakley S; Wills S; Goodman D; Tenney D; Spreng RL; Zhang L; Yates NL; Montefiori DC; Eller MA; Easterhoff D; Hope TJ; Rerks-Ngarm S; Pittisuttithum P; Nitayaphan S; Excler JL; Kim JH; Michael NL; Robb ML; O'Connell RJ; Karasavvas N; Vasan S; Ferrari G; Tomaras GD;
    PLoS Pathog; 2023 May; 19(5):e1011359. PubMed ID: 37256916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.